Can eculizumab be discontinued in aHUS?: Case report and review of the literature

BACKGROUND: The management of atypical hemolytic uremic syndrome (aHUS) has evolved into better control of thrombotic microangiopathy (TMA) and recovery of renal functions since the recent introduction of the terminal complement cascade blocker, eculizumab, into clinical use. Better characterization...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: Sahutoglu, Tuncay, Basturk, Taner, Sakaci, Tamer, Koc, Yener, Ahbap, Elbis, Sevinc, Mustafa, Kara, Ekrem, Akgol, Cuneyt, Caglayan, Feyza Bayraktar, Unsal, Abdulkadir, Daha, Mohamed R.
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2016
Assuntos:
5200
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979790/
https://ncbi.nlm.nih.gov/pubmed/27495036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000004330
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados